Evidence map›Paper›PMID 24648383›Full record

ArticleStem cells (Dayton, Ohio)2014

Gremlin 2 promotes differentiation of embryonic stem cells to atrial fate by activation of the JNK signaling pathway.

Vineeta Tanwar, Jeffery B Bylund, Jianyong Hu, Jingbo Yan, Joel M Walthall, Amrita Mukherjee, William H Heaton, Wen-Der Wang, Franck Potet, Meena Rai and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Stem cells (Dayton, Ohio), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Generation of cardiomyocytes from human-induced pluripotent stem cells resembling atrial cells with ability to respond to adrenoceptor agonists.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. MulticellularFrontiers in cardiovascular medicine · 2020
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Vineeta TanwarDepartment of Medicine, Division of Cardiovascular Medicine, Nashville, Tennessee, USA.
Jeffery B Bylund
Jianyong Hu
Jingbo Yan
Joel M Walthall
Amrita Mukherjee
William H Heaton
Wen-Der Wang
Franck Potet
Meena Rai
Sabina Kupershmidt
Ela W Knapik
Antonis K Hatzopoulos
Vanderbilt University · US

Funding

TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007628 · NIGMS · VANDERBILT UNIVERSITY · PI BARNETT, JOEY VICTOR, KAVALALI, EGE T · 1985 to 2022
$11.2M
Optimizing Cardiovascular Stem Cells for Cardiac Repair and RegenerationU01HL100398 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HATZOPOULOS, ANTONIS · 2009 to 2015
$8.0M
Training In Cardiovascular ResearchT32HL007411 · NHLBI · VANDERBILT UNIVERSITY · PI BECKMAN, JOSHUA A · 1985 to 2020
$7.2M
Wnt-Pathway Modulators in Cardioprotection after IschemiR01HL083958 · NHLBI · VANDERBILT UNIVERSITY · PI HATZOPOULOS, ANTONIS · 2006 to 2010
$2.2M
THE ROLE OF THE SECRETORY PATHWAY IN CRANIOFACIAL MORPHOGENESISR01DE018477 · NIDCR · VANDERBILT UNIVERSITY · PI KNAPIK, ELA W · 2007 to 2010
$1.5M
NHLBI NIH HHS 2T32HL007411-33NHLBI NIH HHS HL083958NHLBI NIH HHS HL100398NHLBI NIH HHS R01 HL083958NHLBI NIH HHS T32 HL007411NHLBI NIH HHS U01 HL100398NIDCR NIH HHS DE018477NIDCR NIH HHS R01 DE018477NIGMS NIH HHS T32 GM007628
6 · The paper itself

Abstract

The bone morphogenetic protein antagonist Gremlin 2 (Grem2) is required for atrial differentiation and establishment of cardiac rhythm during embryonic development. A human Grem2 variant has been associated with familial atrial fibrillation, suggesting that abnormal Grem2 activity causes arrhythmias. However, it is not known how Grem2 integrates into signaling pathways to direct atrial cardiomyocyte differentiation. Here, we demonstrate that Grem2 expression is induced concurrently with the emergence of cardiovascular progenitor cells during differentiation of mouse embryonic stem cells (ESCs). Grem2 exposure enhances the cardiogenic potential of ESCs by 20-120-fold, preferentially inducing genes expressed in atrial myocytes such as Myl7, Nppa, and Sarcolipin. We show that Grem2 acts upstream to upregulate proatrial transcription factors CoupTFII and Hey1 and downregulate atrial fate repressors Irx4 and Hey2. The molecular phenotype of Grem2-induced atrial cardiomyocytes was further supported by induction of ion channels encoded by Kcnj3, Kcnj5, and Cacna1d genes and establishment of atrial-like action potentials shown by electrophysiological recordings. We show that promotion of atrial-like cardiomyocytes is specific to the Gremlin subfamily of BMP antagonists. Grem2 proatrial differentiation activity is conveyed by noncanonical BMP signaling through phosphorylation of JNK and can be reversed by specific JNK inhibitors, but not by dorsomorphin, an inhibitor of canonical BMP signaling. Taken together, our data provide novel mechanistic insights into atrial cardiomyocyte differentiation from pluripotent stem cells and will assist the development of future approaches to study and treat arrhythmias.

Indexed as

Cell DifferentiationMAP Kinase Signaling SystemAnimalsCells, CulturedCytokinesEmbryonic Stem CellsHeart AtriaMiceMyocytes, CardiacProteinsCytokinesGrem2 protein, mouseProteinsAtrial cardiomyocytesBMP SignalingCardiac differentiationEmbryoid bodiesEmbryonic stem cellsPluripotent stem cells

Identifiers

PMID24648383
PMCPMC4123739
OpenAlexW1588365771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.